Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 14/20 | 0.51 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17632022 | 1.00 | USP30 (0.51) | USP30UCHL1MAPTMEN1KMT2A | |
| SCHEMBL17632569 | 0.93 | USP30 (0.52) | USP30UCHL1MAPTMEN1KMT2A | |
| SCHEMBL17632566 | 0.93 | USP30 (0.52) | USP30UCHL1MAPTMEN1KMT2A | |
| SCHEMBL31166695 | 0.88 | ABL1 (0.53) | USP30MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20239929 | 0.87 | UCHL1 (0.49) | USP30UCHL1MAPTMEN1KMT2A | |
| SCHEMBL20239928 | 0.87 | UCHL1 (0.49) | USP30UCHL1MAPTMEN1KMT2A | |
| SCHEMBL31166687 | 0.87 | ABL1 (0.52) | USP30MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31420241 | 0.86 | UCHL1 (0.47) | USP30UCHL1 | |
| SCHEMBL30513241 | 0.86 | UCHL1 (0.46) | USP30UCHL1MAPTMEN1KMT2A | |
| SCHEMBL31420247 | 0.86 | UCHL1 (0.47) | USP30UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335427-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335427-A1 | SMALL MOLECULE INHIBITION OF DEUBIQUITINATING ENZYME JOSEPHIN DOMAIN CONTAINING 1 (JOSD1) AS A TARGETED THERAPY FOR LEUKEMIAS WITH MUTANT JANUS KINASE 2 (JAK2) | JAK1, JAK2, UBQLN1 | USP30 12/4885UCHL1 148/4885MAPT 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.